FibroGen Inc expected to post a loss of 32 cents a share - Earnings Preview

Kyntra Bio

03/08/2024 01:40

* FibroGen Inc  FGEN.OQ   FGEN.O  is expected to show a fall
in
quarterly revenue when it reports  results on August 6 for the
period ending June 30 2024
    * The San Francisco California-based  company is expected to
report a 21.8% decrease in revenue to $34.661 million from
$44.32 million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for FibroGen Inc is for a
loss
of 32 cents per share. 
    * The current average analyst rating on the shares is "sell"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for FibroGen
Inc is
$1.05​, above​ its last closing price of $0.43. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.53       -0.42      -0.33     Beat    21.4
 Dec. 31 2024  -0.43       -0.42      -0.52     Missed  -34.1
 Sep. 30 2023  -0.66       -0.68      -0.52     Beat    23.5​
 Jun. 30 2023  -0.70       -0.70      -0.90     Missed  
 ​​Mar.        -0.72       -0.75      -0.81     Missed  -7.5
 31 2023                                                
 Dec. 31 2022  -0.93       -0.94      -0.70     Beat    25.4​
 Jan. 1 0001   -0.79       -0.81      -0.98     Missed  -21
 Jun. 30 2022  -0.93       -0.94      -0.78     Beat    16.7
 This summary was machine generated August 3 at 00:40 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)